A series of novel isolongifoleno[7,8‐d]thiazolo[3,2‐a]pyrimidine derivatives (4a–4x) were synthesized from isolongifolanone according fragment‐based design strategy, and their anticancer activity against human aortic smooth muscle cells (HASMC), human breast cancer (MCF‐7) cells, human cervical cancer (HeLa) cells, and human liver cancer (HepG2) cells were investigated. Results of the anticancer activity illustrated that most of the compounds showed potent antitumor activity and compound 4i proved to be the most active derivative with IC50 values of 0.33 ± 0.24 (for MCF‐7 cells), 0.52 ± 0.13 (for HeLa cells), and 3.09 ± 0.11 μM (for HepG2 cells), respectively. Moreover, we assessed the effects of 4i on cell apoptosis, cell cycle distribution, mitochondrial membrane potential, and reactive oxygen species (ROS) generation. The results indicated that compound 4i altered mitochondrial membrane potential and produced ROS leading to cell apoptosis of MCF‐7 cells in a dose‐dependent manner, however, without affecting cell cycle progression. These findings suggested that 4i was an effective compound and provided a promising candidate for anticancer drugs.
Synthesis and antitumor activity of isolongifoleno[7,8‐d]thiazolo[3,2‐a]pyrimidine derivatives via enhancing ROS level
Chonghui Ma,Yunyun Wang,Fuhao Dong,Zhonglong Wang,Yuxun Zhao,Y. Shan,W. Gu,Shifa Wang
Published 2019 in Chemical Biology and Drug Design
ABSTRACT
PUBLICATION RECORD
- Publication year
2019
- Venue
Chemical Biology and Drug Design
- Publication date
2019-08-01
- Fields of study
Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-38 of 38 references · Page 1 of 1
CITED BY
Showing 1-12 of 12 citing papers · Page 1 of 1